Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT06225674 |
Other study ID # |
Epi_002 |
Secondary ID |
|
Status |
Recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
November 6, 2023 |
Est. completion date |
March 6, 2024 |
Study information
Verified date |
January 2024 |
Source |
Episurf Medical Inc. |
Contact |
Fredrik Zetterberg |
Phone |
+46 70-839 62 33 |
Email |
fredrik.zetterberg[@]episurf.com |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
This is a retrospective, observational, single-arm, multi-centre, post-market clinical
investigation designed to verify clinical performance and safety of Episealer Talus
post-operation for treatment of focal osteochondral defects on the talus bone in the ankle.
This retrospective investigation aims to collect data from patients with focal osteochondral
defects treated with Episealer Talus, to provide insight on the potential benefit of
Episealer Talus in the treatment of focal osteochondral defects.
The aim for the clinical investigation is to collect data from approximately 25 adult
subjects who were treated for focal osteochondral defect with Episealer Talus implant in 6
clinics (Sweden and Germany) since January 2020, when the devices were CE-marked. The data
collected for each subject will include demographics and data generated in relation to the
surgery itself and the post-surgery phases including e.g. focal defect grade and position,
collected through medical record review. Each subject will also be asked to complete a set of
QoL questionnaires (SEFAS, FAOS and VAS).
Description:
This is a retrospective, observational, single-arm, multi-centre, post-market clinical
investigation designed to verify clinical performance and safety of Episealer Talus
post-operation for treatment of focal OCDs. The overall clinical investigation is based on
the patient's reported outcome (PROs) from OCD patients previously treated with Episealer
Talus implant after January 2020. In total approximately 25 adult subjects, male or female,
from 6 clinics (Sweden and Germany) will be included in the investigation.
Subjects will be identified by the investigational site team through medical record review
and/or site knowing the subjects from performing the implantation after January 2020.
Following collection of the subject´s signed informed consent, subject demographics, health-
and surgery-related data will be collected from the subjects' medical records. Therefore,
only one visit is planned for each subject during the clinical investigation. The performance
variables relate to quality of life, and all subjects will be asked to fill in three
questionnaires (SEFAS, FAOS and VAS).
The overall duration of the investigation is estimated to be 4 months, including a 1 month
recruitment period. Each subject is estimated to spend approximately 1-2 hour for completing
the informed consent and completing the questionnaires. Subject´s participation in the
clinical investigation will be terminated once the questionnaires have been completed and the
site team considers all data collected for the subject.